A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, placebo controlled study that will evaluate the efficacy
and safety of PCS499 as compared to placebo for the treatment of ulcerations of patients with
necrobiosis lipoidica (NL) and will inform the design of future studies. Approximately 20
ulcerated NL patients who also meet other inclusion/exclusion criteria will be enrolled in
the study. The primary objective of this study is to evaluate the efficacy of PCS499 as
compared with placebo in ulcerated patients with Necrobiosis Lipoidica.